.png)
.png)
Latest news from BIA
BioIndustry Association/Informa Biotech Financing Update shows strong venture capital fundraising by sector as momentum continues to build for biotech financing in 2018
The BIA/Informa Biotech Financing Update March-May 2018 released today shows that UK biotech companies’ ability to attract financing continues to build momentum after a solid start to the year.
Pharmaceutical industry responds to Trade Bill amendment on medicines
Parliament has voted in favour of amendment NC17 to the Trade Bill that will make it a negotiating objective for the UK Government to seek the UK's participation in the European medicines regulatory network.
Joint statement from BIA/ABPI on EU Council meeting
At the end of June's EU Council meeting, Steve Bates, chief executive of the BIA and Mike Thompson, chief executive of the ABPI said:
BIA responds to new government investment to attract world's best in science and innovation
The BIA has to responded to the announcement from government of the inaugural UKRI Future Leaders Fellowship Scheme will receive £900 million over the next 11 years. BIA CEO Steve Bates said: “Today’s announcement will help to boost innovation in the UK and I am delighted to see that businesses will be able to use this scheme. It is vital that the UK government continues to support young entrepreneurs and business leaders to secure the innovation pipeline in the UK for the future.”
Blue Earth Diagnostics shortlisted for prestigious “Best Emerging Biotech Company” award
Oxford, UK – August 9, 2018 – Blue Earth Diagnostics, a leading molecular imaging diagnostics company, yesterday announced that it has been shortlisted as a finalist in the 2018 OBN awards in the category “Best Emerging Biotech Company”. These prestigious awards, which are judged by a panel of leading industry entrepreneurs and experts, celebrate innovation and outstanding achievement across the UK’s Life Sciences industry.
Synthace Appoints Susan Shiff, PhD, MBA, to Board of Directors
Synthace Ltd., the company behind the leading cloud software platform for automating and improving the success rate of biological research and development today announced the appointment of Susan Shiff Ph.D., MBA, to its board of directors.
Leaf Expression Systems appoints Simon Saxby as new Chief Executive Officer
Norwich, UK: Leaf Expression Systems, a contract development business specialising in plant expression of proteins, metabolites and complex natural products, announced today that life sciences veteran Simon J.Y Saxby has joined the company as CEO. The appointment comes as Leaf Expression System’s multi-million pound purpose-built facility on the Norwich Research Park becomes fully operational amidst growing interest worldwide in its game-changing plant expression technology, Hypertrans®.
Arecor to give a short course and present at the Bioprocessing Summit, 13th-17th August 2018
Cambridge, UK., 9th August 2018: Arecor Ltd (“the Company”), the UK-based leading formulation technology company, focused on developing superior biopharmaceuticals via the innovative reformulation of proteins and peptides, is pleased to announce its participation at the Bioprocessing Summit, 13th-17th August 2018, at the Sheraton Boston Hotel, Boston, Massachusetts, USA.
Video of the week: Opening of the Schrödinger Building 2018
The Schrödinger Building on The Oxford Science Park was opened in July 2018 by Sam Gyimah MP, Minister of State for Universities, Science, Research & Innovation. This film highlights some of the work going on there & the importance of the building in the local innovation environment.
The Evolution of Advanced Therapies –Phacilitate Leaders Europe Conference
The first half of 2018 has delivered several pivotal developments for the advanced therapies industry. The year began with two significant acquisitions – in January Celgene acquired Juno for $9bn and Sanofi acquired Bioverativ for $11.5bn - and the EMA recently approved the first two CAR-T cell medicines – Novartis’ Kymriah and Kite’s Yescarta. This follows a bumper year for the sector in 2017, in which Kymriah and Yescarta both received FDA approval and Gilead acquired Kite for $11.9bn. So how long will this trend continue? How can the advanced therapies industry maintain and build on this momentum and does the industry need to adapt and evolve to ensure sustainable success?
CEO Update: Monday 13 July
As we communicated in last week’s Newscast, the government has published guidance documents which offer a certain amount of clarity on how life sciences companies will be able to operate during an implementation period. I’d encourage you to look at these if you have not already done so. BIA Member Cancer Research UK has also published a policy statement on the future of clinical trials as the UK leaves the EU, which gives an insight into just some of the concerns delays at the borders may cause. Clinical trials to treat neuroblastoma, a rare and aggressive cancer most often affecting babies and children, involve the use of iodine-124, a radioactive material.
Video of the week: The first IVF baby visits the Science Museum
Louise Brown was a miracle baby like no other - the first baby born using IVF. She was born on 25 July 1978, having been conceived using a technique devised by British researchers Robert Edwards, Patrick Steptoe and Jean Purdy. 40 years after her birth, and 6 million IVF babies later, this technology continues to bring hope and happiness to many couples.
Please find a selection of featured BIA publications below. To see our full publications library, click here.
Influencing and shaping our sector, BIA update: January - April 2018
This quarterly update gives an overview of key policy developments and the BIA’s continued engagement with policymakers, regulatory authorities and wider stakeholders on behalf of the UK life sciences industry, from January to April 2018.
Biotech Financing Update: December 2017 to February 2018
The BIA/Informa Biotech Financing Update: December 2017-February 2018 released today shows that venture capital financing and follow on financing on the public markets are off to a solid start in 2018.
Pipeline Progressing: The UK's Global Bioscience Cluster in 2017
A new report released by the BioIndustry Association (BIA) and Informa Pharma Intelligence reveals that the UK has the strongest clinical and preclinical pipeline in Europe.
BIA Best practice guide for communicating R&D
Ensuring investors and the wider public are well informed and confident about bioscience is crucial to the success of individual companies and the sector as a whole. To support the sector to maintain high standards in communications about R&D progress, the BIA has produced a best practice guide for bioscience companies with a supporting library of resources.
